Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure

NCT02232581 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Alovudine - low
DRUG: Alovudine - medium
DRUG: Alovudine - high
DRUG: Placebo

Sponsor

Boehringer Ingelheim